Semarion

📍 Cambridge, United Kingdom🗓 Founded 2018👥 13 employees💰 Last funded Mar 2026
Unlock more data from adherent cell assays. Our SemaCyte® platform turns adherent cells into barcoded, assay-ready, automation-friendly reagents, enabling researchers to multiplex cell models within a single well and dramatically increase experimental throughput. SemaCyte® microcarriers are ultra-miniaturised, barcoded micro-wells that carry small colonies of adherent cells while preserving their natural morphology. These microcarriers can be moved with standard liquid handling tools, cryopreserved in biobanks, pooled for multiplexed experiments, and decoded using optical barcodes. By transforming adherent cells into mobile, automation-ready reagents, SemaCytes enable researchers to: • Multiplex different cell models within a single well • Generate assay-ready adherent cells that can be thawed and used on demand • Reduce assay preparation time and increase throughput by up to 10× • Integrate seamlessly with standard microplate workflows, automation, and imaging systems Semarion is a University of Cambridge spin-out from the Cavendish Laboratory, combining materials science, microfabrication, and cell biology to remove bottlenecks in adherent cell screening. We collaborate with leading pharmaceutical companies and technology partners to bring scalable multiplexed cell assays to laboratories worldwide.
2
Total investors
0
Early stage
1
Mid stage
1
Late stage
2018
Founded
Investor geography1 country
United Kingdom
2
Frequently asked questions
Who invested in Semarion?
Semarion has 2 investors on record on gritt.io, 1 mid-stage and 1 late-stage investors.
When did Semarion last raise funding?
The most recent investment in Semarion recorded on gritt.io was in March 2026.
When was Semarion founded?
Semarion was founded in 2018.
What industry is Semarion in?
Semarion operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Semarion based?
Semarion is headquartered in Cambridge, United Kingdom.